A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #953

Five primary melanomas in situ in a patient with recent tanning bed use, melanotan exposure, and anabolic hormone use.

Vadner DJ, Smith S JAAD case reports. 2026.
Weak / noneCase reportMentions: Melanotan II

Editor's note

This single case report describes multiple in-situ melanomas in a patient with several concurrent exposures, including melanotan, tanning beds, and anabolic hormones. With multiple confounding factors and a sample of one, it cannot attribute causation to any single agent. Relevant to the safety discussion around unregulated melanotan use, with appropriate caution about what a case report can show.

Plain-language abstract

A case report describes a patient who developed five early-stage melanomas after recent tanning bed use, melanotan exposure, and anabolic hormone use.